Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Martin Allen-Auerbach, M.D.
Martin Allen-Auerbach, M.D.


Nuclear Medicine

General Information:

English, German, Spanish, Swedish


Associate Clinical Professor, Department of Molecular and Medical Pharmacology
Director, Positron Emission Tomography/Computed Tomography, Santa Monica Nuclear Medicine Services
Director, Nuclear Medicine
Member, JCCC Community

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica


Nuclear Medicine, UCLA School of Medicine, 2002 - 2003
Research Fellowship, UCLA School of Medicine, 1997 - 1998
Internal Medicine, New York University Downtown Hospital, 2000 - 2002
Internal Medicine, New York University Downtown Hospital, 1999 - 2000
Medical Degree:
M.D., Universitat Wien Medizinische Fakultat, 1995


Board Certification(s):
Nuclear Medicine, American Board of Nuclear Medicine, 2003, 2012

Contact Information:

(310) 983-1444

Scientific Interest(s):

Dr. Martin Allen-Auerbach serves as attending physician in nuclear medicine at the UCLA Santa Monica and Westwood hospitals. His active research includes clinical studies investigating the role of molecular imaging with PET/CT to gain insights into malignant disease processes and monitoring of cancer treatment.

Selected Cancer-Related Publications:

Allen-Auerbach M, de Vos S, Czernin J. PET/computed tomography and lymphoma. Radiol Clin North Am. 2013 Sep;51(5):833-44. doi: 10.1016/j.rcl.2013.05.004. Epub 2013 Jul 9.

Karantanis D, Kalkanis D, Allen-Auerbach M, Bogsrud TV, Subramaniam RM, Danielson A, Lowe VJ, Czernin J. Oncologic 18F-FDG PET/CT: referring physicians' point of view. J Nucl Med. 2012 Oct;53(10):1499-505. doi: 10.2967/jnumed.111.102228. Epub 2012 Aug 23.

Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med. 2011 Nov;52(11):1684-9. doi: 10.2967/jnumed.111.095257.